

**Panel on Health Services**

**List of follow-up actions**

(Position as at 22 April 2014)

<b>Subject</b>	<b>Date of meeting</b>	<b>Follow-up action required</b>	<b>Administration's response</b>
1. Regulation and control of pharmaceutical products in Hong Kong	31 March 2009	The Administration was requested to provide the revised checklist used by the inspectors of the Department of Health ("DH") when conducting inspections on pharmaceutical manufacturers once they were finalized.	The Review Committee on Regulation of Pharmaceutical Products in Hong Kong recommended DH in January 2010 to upgrade Hong Kong's current Good Manufacturing Practices ("GMP") licensing standards by a phased approach to the international standards promulgated by the World Health Organization and Pharmaceutical Inspection Co-operation Scheme ("PIC/S"). On DH's invitation, PIC/S conducted a gap assessment between the standards of GMP and PIC/S in end-2010. DH procured a consultancy service in July 2012 for advice on upgrading the current GMP licensing standards to PIC/S standards. It is expected that the consultancy will be completed in 2014. The inspection checklist will be revised in accordance with the advice of the consultant and submitted to the Panel once available.

<b>Subject</b>	<b>Date of meeting</b>	<b>Follow-up action required</b>	<b>Administration's response</b>
2. Creation of new directorate posts in DH	11 April 2011	The Administration was requested to report on a quarterly or bi-annual basis the progress in taking forward the recommendations of the Review Committee on the Regulation of Pharmaceutical Products in Hong Kong after the establishment of the Office on Drugs.	<p>The Assistant Director (Drug) and one Chief Pharmacist posts were created on 1 and 14 September 2011 respectively for the setting up of the Drug Office to take forward the recommendations of the Review Committee on the Regulation of Pharmaceutical Products in Hong Kong ("Review Committee").</p> <p>The Administration consulted the Panel on 18 November 2013 in relation to the legislative proposals to implement some of the Review Committee's recommendations, which sought to enhance the regulation of pharmaceutical products. The Administration also attended special meetings of the Panel respectively on 10 December 2013 and 10 February 2014 to exchange views with deputations and Members on the legislative proposals.</p> <p>The Administration introduced the legislative proposals, i.e. the Pharmacy and Poisons (Amendment) Bill 2014, into the Legislative Council on 26 March 2014.</p>

Subject	Date of meeting	Follow-up action required	Administration's response
3. Pilot project on enhancing radiological investigation services through collaboration with the private sector	12 December 2011	The Administration was requested to provide data on the average waiting time of cancer patients for radiological investigation services before and six months after implementation of the pilot project.	The Administration will provide a response in due course.
4. An overview of the re-development and expansion plans of public hospitals	15 July 2013	The Administration was requested to provide a breakdown of the catchment population, the number of beds per 1 000 population, the range of services (including those services that had yet been provided because of manpower constraint or other reasons, and the respective proportion of services provided to patients within and outside the catchment area of the hospital cluster concerned), the manpower shortfall of doctors and nurses, as well as the anticipated changes in the above areas for the next fifteen years (at five-year intervals), by hospital clusters.	The Administration will provide a response in due course.
5. Dental care policy and services for the elderly and people with disabilities	16 December 2013	The Administration was requested to provide information on -  (a) the financial implications for increasing the number of	The Administration will provide a response in due course.

<b>Subject</b>	<b>Date of meeting</b>	<b>Follow-up action required</b>	<b>Administration's response</b>
		<p>government dental clinics to cover all 18 districts in the territory and expanding the scope of services of the clinics to include oral check-up and other curative treatments (e.g. fillings) for the general public;</p> <p>(b) a comparison of the amount of public expenditure on dental care services and its percentage share in public health expenditure in Hong Kong and that of other developed countries such as the United States and major European countries;</p> <p>(c) the oral health conditions (in terms of tooth loss and decay experience) of institutionalized older persons aged 65 and above as captured by OHS 2001 and OHS 2011; and</p> <p>(d) whether non-institutionalized older persons aged 75 and above and people with disabilities were covered by OHS 2011, and if not, the reasons for that.</p>	

<b>Subject</b>	<b>Date of meeting</b>	<b>Follow-up action required</b>	<b>Administration's response</b>
6. Resources allocation among hospital clusters by the Hospital Authority	20 January 2014	<p>The Administration was requested to provide -</p> <p>(a) the relevant papers of the Hospital Authority Review Steering Committee on matters concerning the resources management system within the Hospital Authority ("HA"); and</p> <p>(b) information on the amount of funding allocated to each public hospital in the past five years, with a breakdown by (i) the funding to sustain the baseline operations of respective hospitals; (ii) additional funding to deliver the new services that had been supported during the annual service planning process; and (iii) other funding to address specific pressure areas/gaps. The information on (i), (ii) and (iii) should include a further breakdown by manpower, drugs, equipment, facilities and other operating needs.</p>	The Administration will provide a response in due course.

Subject	Date of meeting	Follow-up action required	Administration's response
7. Legislative proposals to enhance the regulation of pharmaceutical products	10 February 2014	The Administration was requested to provide the numbers of inspection conducted, prosecution instituted and conviction secured in relation to non-compliance with regulation 19(2)(a) of the Pharmacy and Poisons Regulations (Cap. 138A) in the past five years.	The Administration's response was issued to members vide LC Paper No. CB(2)1284/13-14(01) on 10 April 2014.
8. Surgical Outcomes Monitoring and Improvement Programme of the Hospital Authority	10 February 2014	The Administration was requested to provide the methodology used in, and the outcome of, HA's recent study on resources utilization by its patient populations which had taken into account cross-cluster utilization of hospital services, including a breakdown of the average resources utilized by each patient by hospital clusters.	The Administration will provide a response in due course.
9. General Outpatient Clinic Public-Private Partnership Programme in Kwun Tong, Wong Tai Sin and Tuen Mun districts and progress of other public-private partnership initiatives on chronic disease management	17 February 2014	The Administration was requested to provide information on -  (a) the total expenditure (including the service fees to participating private doctors, and the costs for drugs and relevant laboratory and x-ray services provided by HA) incurred under the Tin Shui Wai Primary	The Administration will provide a response in due course.

Subject	Date of meeting	Follow-up action required	Administration's response
		<p>Care Partnership Project and the average cost per consultation per participating patient;</p> <p>(b) in case the private doctors participating in the General Outpatient Clinic Public-Private Partnership Programme ("the Programme") provided both chronic and acute care in a single consultation, the service fee to be provided by HA to the doctor for that consultation; and</p> <p>(c) the arrangement to reimburse the participating private doctors the service fees borne by HA under the Programme.</p>	
<p>10. Drug Formulary of the Hospital Authority and the Samaritan Fund</p>	<p>17 March 2014</p>	<p>The Administration was requested to provide information on -</p> <p>(a) outcomes of the cost-effectiveness studies on individual drugs as measured by the quality-adjusted life years conducted by the Drug Management Committee and the then Drug Utilization Review Committee since the introduction</p>	<p>The Administration will provide a response in due course.</p>

<b>Subject</b>	<b>Date of meeting</b>	<b>Follow-up action required</b>	<b>Administration's response</b>
		<p>of the HA Drug Formulary in 2005, including the findings of those overseas studies to which the Committees had made reference;</p> <p>(b) a breakdown by the types of rare disease identified by the World Health Organization of the number of patients receiving treatments in HA who were suffering from rare diseases and the drugs and/or treatment provided to these patients;</p> <p>(c) the number of resected colon cancer patients receiving treatments in HA who had to purchase Oxaliplatin at their own expenses before the drug was repositioned as Special Drug in the HA Drug Formulary in April 2012; and</p> <p>(d) whether the prescription of drugs for patients suffering from the same disease and with similar clinical conditions would vary among different hospital clusters due to the difference in resources</p>	

<b>Subject</b>	<b>Date of meeting</b>	<b>Follow-up action required</b>	<b>Administration's response</b>
		available for individual hospital clusters to purchase drugs.	
11. Development of Chinese medicine and Integrated Chinese-Western Medicine Project	17 March 2014	The Administration was requested to consider subjecting the Integrated Chinese-Western Medicine Pilot Project to ethical review, and provide a copy of the relevant application for ethical approval for reference of the Panel when available.	The Administration will provide a response in due course.